AI Antibiotic Discoveries Win 2026 Pritzker Prize
The award honors laboratory discoveries of new antibiotics, and no clinical timeline has been announced for the compounds.
Updated on Nov. 2, 2026 in Life Sciences
Live Poll
Do you think AI will meaningfully speed up the discovery of new medicines?
Regina Barzilay and James Collins were named recipients of the 2026 Pritzker Prize for AI in Science Research Excellence, recognized for joint work in AI-enabled antibiotic discovery. The award is for research-stage and demonstrated laboratory discovery work rather than a shipped clinical product.
Why it matters
The pair's 2020 Cell paper described halicin, identified by a deep learning model trained on 2,500 molecules, and their 2023 identification of abaucin extended the approach. The work matters as antimicrobial resistance grows, and the extraction describes a discovery process that once took years being completed in a few weeks.
The halicin model was trained on a set of 2,500 molecules and identified a compound that killed resistant pathogens including Clostridium difficile, Acinetobacter baumannii, and Mycobacterium tuberculosis. The extraction gives no clinical performance figures or comparator benchmarks against conventional screening.
The players
Regina Barzilay
Computer scientist at MIT who co-led AI-driven antibiotic discovery work, including the halicin study.
James Collins
Biomedical engineer at MIT who co-led the halicin and abaucin research and is a 2026 Pritzker Prize recipient.
The details
Researchers trained a deep learning model, a type of machine learning system that learns patterns from labeled examples, on a set of 2,500 molecules and used it to flag candidates with antibacterial activity. The model's first flagged compound, halicin, was then tested against resistant bacteria, including Clostridium difficile, Acinetobacter baumannii, and Mycobacterium tuberculosis. Abaucin, identified in 2023 with machine learning, is described as a narrow-spectrum antibiotic effective against A. baumannii, meaning it targets a specific group of bacteria rather than many types at once.
Timeline
2020: Barzilay and Collins published the halicin paper in Cell.
2023: Abaucin was identified using machine learning.
2024: The Pritzker Prize for AI in Science was established.
November 2, 2026: The 2026 prize was awarded to Barzilay and Collins.
The Tech Race
The halicin paper is the first documented case of an AI-discovered antibiotic in the extraction, setting the precedent for the abaucin identification in 2023. The 2026 Pritzker Prize marks recognition of this approach as a distinct research track within drug discovery.
The extraction does not report availability, pricing, or dates for any AI-discovered antibiotic reaching patients. Readers should not expect these compounds in clinical use based on this award alone.
The takeaway
Watch for clinical trial results or regulatory filings for halicin or abaucin, which would show whether lab-stage discovery translates into treatments. The extraction gives no date for either milestone.
Further reading
For broader context on how computing is reshaping biology, see the Life Sciences section.
Source note: This article includes information reported by MIT News | Massachusetts Institute of Technology.
Live Poll
Do you think AI will meaningfully speed up the discovery of new medicines?
